Immuneering Corporation
IMRXNASDAQHealthcareBiotechnology
Previous close
$5.30
+$0.05 · +0.95%
IMRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
39
Expensive
Momentum
41
Neutral
Sentiment
76
Bullish
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteImmuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Benjamin J. Zeskind
- Listed since
- Jul 30, 2021
- Employees
- 57
Market position
Day range
Current $5.30
52-week range
Current $5.30
- Open
- $5.35
- Previous close
- $5.25
- Volume
- 445.72K
- 0.35× average
- Average volume
- 1.27M
- Average daily volume
- Market cap
- 192.4M USD
- Beta
- 0.37
- Market reference 1
- 50-day average
- $4.7085
- +12.56% above average
- 200-day average
- $5.3368
- -0.69% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 164.78M USD
- P/E (TTM)
- -5.1×
- P/B (TTM)
- 1.8×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.98×
- Earnings yield
- -19.35%
- Free cash flow yield
- -15.71%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -25.64%
- Return on assets
- -24.15%
- Return on invested capital
- -26.71%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 17.5×
- Altman Z-score
- 7.92
- Piotroski F-score
- 2 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 316.95K USD | 2.08M USD |
| Cost of goods sold | 698.89K USD | — | — | 158.12K USD | 1.15M USD |
| Gross profit | −698.89K USD | — | — | 158.83K USD | 926.89K USD |
| Research and development | 42.05M USD | 47.96M USD | 41.62M USD | 36.27M USD | 26.54M USD |
| Selling, general, and administrative | 17.3M USD | 16.08M USD | 16.76M USD | 15.61M USD | 8.27M USD |
| Operating expenses | 58.68M USD | 64.07M USD | 58.41M USD | 51.9M USD | 34.81M USD |
| Interest income | 3.04M USD | 2.59M USD | 3.61M USD | 1.01M USD | 169.9K USD |
| Depreciation and amortization | 698.89K USD | 385.07K USD | 352.08K USD | 277.25K USD | 159.07K USD |
| Operating income | −59.38M USD | −64.07M USD | −58.41M USD | −51.74M USD | −33.89M USD |
| Net income | −56.02M USD | −61.04M USD | −53.47M USD | −50.51M USD | −33.54M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 36%
- 4 beats, 6 misses, 1 met estimate
- Average EPS surprise
- +2.40%
- 11 comparable reports
- Latest EPS result
- -0.27
- Estimate -0.26 · Miss by 2.16%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$14.33
170.38% upsideRating distribution
11 ratingsRecent analyst actions
IMRX news
IMRX peers
ETFs holding IMRX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM7.05M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI6.71M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF2.61M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN2.59M0.02%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB2.24M0.02%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO1.24M0.01%17.4B USD0.06%$121.25+0.74%
iShares Micro-Cap ETFIWC977.15K0.06%1.53B USD0.60%$198.39+1.10%
ALPS Medical Breakthroughs ETFSBIO403.78K0.17%236.37M USD0.50%$69.11+0.80%iShares Russell 2000 ETFIWM- Market value
- 7.05M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 6.71M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 2.61M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 2.59M
- Weight
- 0.02%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 2.24M
- Weight
- 0.02%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.24M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Micro-Cap ETFIWC- Market value
- 977.15K
- Weight
- 0.06%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
ALPS Medical Breakthroughs ETFSBIO- Market value
- 403.78K
- Weight
- 0.17%
- AUM
- 236.37M USD
- Expense ratio
- 0.50%
- Price / 1D
- $69.11+0.80%
Continue in GoAI
Research IMRXresearch.disclaimer